Literature DB >> 20088930

Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

A Gézsi1, U Budde, I Deák, E Nagy, A Mohl, A Schlammadinger, Z Boda, T Masszi, J E Sadler, I Bodó.   

Abstract

BACKGROUND: von Willebrand disease (VWD) Vicenza is characterized by low plasma von Willebrand factor (VWF) levels, the presence of ultra-large (UL) VWF multimers and less prominent satellite bands on multimer gels, and the heterozygous amino acid substitution R1205H in the VWF gene. The pathogenesis of VWD Vicenza has been elusive. Accelerated clearance is implicated as a cause of low VWF level.
OBJECTIVES: We addressed the question, whether the presence of ultra-large multimers is a cause, or a result of accelerated VWF clearance, or whether it is an unrelated phenomenon. PATIENTS/
METHODS: We studied the detailed phenotype of three Hungarian patients with VWD Vicenza, expressed the mutant VWF-R1205H in 293T cells and developed a mathematical model to simulate VWF synthesis and catabolism.
RESULTS: We found that the half-life of VWF after DDAVP was approximately one-tenth of that after the administration of Haemate P, a source of exogenous wild-type (WT) VWF (0.81 + or - 0.2 vs. 7.25 + or - 2.38 h). An analysis of recombinant mutant VWF-R1205H showed that the biosynthesis and multimer structure of WT and mutant VWF were indistinguishable. A mathematical model of the complex interplay of VWF synthesis, clearance and cleavage showed that decreasing VWF half-life to one-tenth of normal reproduced all features of VWD Vicenza including low VWF level, ultra-large multimers and a decrease of satellite band intensity.
CONCLUSION: We conclude that accelerated clearance alone may explain all features of VWD Vicenza.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088930      PMCID: PMC3863617          DOI: 10.1111/j.1538-7836.2010.03753.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  22 in total

1.  Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families.

Authors:  R Schneppenheim; A B Federici; U Budde; G Castaman; E Drewke; S Krey; P M Mannucci; G Riesen; F Rodeghiero; B Zieger; R Zimmermann
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

2.  The elusive pathogenesis of von Willebrand disease Vicenza.

Authors:  Giancarlo Castaman; Francesco Rodeghiero; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation.

Authors:  G Castaman; E Missiaglia; A B Federici; R Schneppenheim; F Rodeghiero
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

4.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

5.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

6.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

7.  Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?

Authors:  S A Brown; A Eldridge; P W Collins; D J Bowen
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

8.  von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.

Authors:  P M Mannucci; R Lombardi; G Castaman; J A Dent; A Lattuada; F Rodeghiero; T S Zimmerman
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.

Authors:  Peter J Lenting; Erik Westein; Virginie Terraube; Anne-Sophie Ribba; Eric G Huizinga; Dominique Meyer; Philip G de Groot; Cécile V Denis
Journal:  J Biol Chem       Date:  2003-11-12       Impact factor: 5.157

10.  Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.

Authors:  Alessandra Casonato; Elena Pontara; Francesca Sartorello; Maria Grazia Cattini; Maria Teresa Sartori; Roberto Padrini; Antonio Girolami
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

View more
  6 in total

Review 1.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

2.  Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

Authors:  Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

Review 3.  New insights into genotype and phenotype of VWD.

Authors:  Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 4.  Diagnosing von Willebrand disease: genetic analysis.

Authors:  Anne Goodeve
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.

Authors:  Alessandra Casonato; Eva Galletta; Federico Galvanin; Viviana Daidone
Journal:  EJHaem       Date:  2021-05-05

6.  A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Authors:  Agnès Veyradier; Pierre Boisseau; Edith Fressinaud; Claudine Caron; Catherine Ternisien; Mathilde Giraud; Christophe Zawadzki; Marc Trossaert; Nathalie Itzhar-Baïkian; Marie Dreyfus; Roseline d'Oiron; Annie Borel-Derlon; Sophie Susen; Stéphane Bezieau; Cécile V Denis; Jenny Goudemand
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.